Sanofi to Acquire Tidal Therapeutics for ~$470M
Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021
Shots:
- Sanofi to acquire Tidal Therapeutics for $160M up front and ~ $310M following the achievement of certain milestones
- The acquisition will add Tidal’s innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
- With its acquisition, Sanofi will further develop the technology platform to expand its research capabilities in immuno-oncology and inflammatory diseases. The technology platform has the potential to bring CAR-T cell therapy to a broader population
Click here to read full press release/ article | Ref: GlobeNewswire | Image: MedCity News